Share This Article
As the IPO Market Reopens, Our "Rich Folks" Profit Play Has Burst Back to Life
No question, the IPO market has made a true resurgence.
True, we saw a bleak first quarter and a very quiet summer.
How would you like to put an extra $125,000 in your nest egg? You can potentially do it this year - and you'll only have to risk $20 to learn how. Click here.
Email this Article
For the best investments to add a little high-potential punch to your portfolio, nothing's better than biotech.
The iShares Nasdaq Biotechnology Exchange Traded Fund (ETF) (Nasdaq: IBB) rose 30.2% in the last 12 months and is already up a healthy 16.5% year to date.
In fact, the biotech sector has been a consistent performer for investors. The Nasdaq Biotechnology Index has notched 16.1% annualized returns for the last five years.
Big gains from just three stocks — Amgen Inc. (Nasdaq: AMGN), BiogenIdec Inc. (Nasdaq: BIIB) and Gilead Sciences Inc. (Nasdaq: GILD) — created a whopping $60 billion in combined shareholder gains in 2012.
And analysts expect the trend to continue.